Systemic lupus erythematosus: modern strategies for management – a moving target

Food and Drug Administration (FDA). Guidance for Industry on Systemic Lupus Erythematosus Developing Drugs for Treatment. From http://wwwfdagov/ohrms/dockets/dockets/05d0106/05d0106htm. Karsh, 1980, Comparative effects of aspirin and ibuprofen in the management of systemic lupus erythematosus, Arthritis & Rheumatism, 23, 1401, 10.1002/art.1780231215 Wallace, 1989, NSAID usage patterns by rheumatologists in the treatment of SLE, The Journal of Rheumatology, 16, 557 Ballas, 1982, Sulindac-induced aseptic meningitis, Archives of Internal Medicine, 142, 165, 10.1001/archinte.142.1.165 Ruppert, 1981, Tolmetin-induced aseptic meningitis, Journal of American Medical Association, 245, 67, 10.1001/jama.245.1.67 Weksler, 1991, Naproxen-induced recurrent aseptic meningitis, DICP, 25, 1183, 10.1177/106002809102501106 Brezin, 1979, Reversible renal failure and nephrotic syndrome associated with nonsteroidal anti-inflammatory drugs, The New England Journal of Medicine, 301, 1271, 10.1056/NEJM197912063012306 Shoenfeld, 1980, Sensitization to ibuprofen in systemic lupus erythematosus, Journal of American Medical Association, 244, 547, 10.1001/jama.244.6.547 Bombardier, 2000, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group, The New England Journal of Medicine, 343, 1520, 10.1056/NEJM200011233432103 Mukherjee, 2001, Risk of cardiovascular events associated with selective COX-2 inhibitors, Journal of American Medical Association, 286, 954, 10.1001/jama.286.8.954 Fessler, 2005, Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual, Arthritis & Rheumatism, 52, 1473, 10.1002/art.21039 Hodis, 1993, The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus, The Journal of Rheumatology, 20, 661 Petri, 1994, Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis, American Journal of Medicine, 96, 254, 10.1016/0002-9343(94)90151-1 Wallace, 1990, Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids, American Journal of Medicine, 89, 322, 10.1016/0002-9343(90)90345-E Edwards, 1997, Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice, Circulation, 96, 4380, 10.1161/01.CIR.96.12.4380 Jancinova, 1994, On the inhibitory effect of chloroquine on blood platelet aggregation, Thrombosis Research, 74, 495, 10.1016/0049-3848(94)90270-4 Costedoat-Chalumeau, 2007, Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus, Annals of the Rheumatic Diseases, 66, 821, 10.1136/ard.2006.067835 Bernstein, 1983, Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy, American Journal of Medicine, 75, 25, 10.1016/0002-9343(83)91267-6 Easterbrook, 2003, Dosage of hydroxychloroquine should be based on ideal body weight: comment on the letter by Alarcon, Arthritis & Rheumatism, 48, 863, 10.1002/art.10749 Feldmann, 1994, The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus, Dermatology, 189, 425, 10.1159/000246899 Wallace, 2007, Antimalarial Therapies, 1152 Lahita, 1987, Low plasma androgens in women with systemic lupus erythematosus, Arthritis & Rheumatism, 30, 241, 10.1002/art.1780300301 Straub, 1996, Dehydroepiandrosterone sulfate is positively correlated with soluble interleukin 2 receptor and soluble intercellular adhesion molecule in systemic lupus erythematosus, The Journal of Rheumatology, 23, 856 Suzuki, 1996, Hormones and lupus: defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosus, Annales de médecine interne, 147, 248 Verthelyi, 2001, Disassociation of sex hormone levels and cytokine production in SLE patients, Lupus, 10, 352, 10.1191/096120301674365881 Chang, 2002, Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, 46, 2924, 10.1002/art.10615 van Vollenhoven, 1995, Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial, Arthritis & Rheumatism, 38, 1826, 10.1002/art.1780381216 Petri, 2002, Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial, Arthritis & Rheumatism, 46, 1820, 10.1002/art.10364 van Vollenhoven, 1999, A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus, Lupus, 8, 181, 10.1191/096120399678847588 Pollak, 1982, Evaluation of treatment in lupus nephritis: effects of prednisone, American Journal of kidney diseases, 2, 170 Pollak, 1964, The natural history of the renal manifestations of systemic lupus erythematosus, The Journal of laboratory and clinical medicine, 63, 537 Kirou, 2007, Systemic Glucocorticoid Therapy in Systemic Lupus Erythematosus. Dubois' Lupus Erythematosus, 1175 Austin, 1986, Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs, The New England Journal of Medicine, 314, 614, 10.1056/NEJM198603063141004 Boumpas, 1992, Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis, Lancet, 340, 741, 10.1016/0140-6736(92)92292-N Gourley, 1996, Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial, Annals of Internal Medicine, 125, 549, 10.7326/0003-4819-125-7-199610010-00003 Illei, 2001, Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis, Annals of Internal Medicine, 135, 248, 10.7326/0003-4819-135-4-200108210-00009 Houssiau, 2002, Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide, Arthritis & Rheumatism, 46, 2121, 10.1002/art.10461 Ballou, 1982, Clinical features of systemic lupus erythematosus: differences related to race and age of onset, Arthritis & Rheumatism, 25, 55, 10.1002/art.1780250109 Nissenson, 1990, Outcome of end-stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders, The Quarterly Journal of medicine, 74, 63 Ward, 1990, Clinical manifestations of systemic lupus erythematosus. Identification of racial and socioeconomic influences, Archives of Internal Medicine, 150, 849, 10.1001/archinte.150.4.849 Dooley, 1997, Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network, Kidney International, 51, 1188, 10.1038/ki.1997.162 Houssiau, 2004, Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial, Arthritis & Rheumatism, 50, 3934, 10.1002/art.20666 Chan, 2000, Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group, The New England Journal of Medicine, 343, 1156, 10.1056/NEJM200010193431604 Hu, 2002, Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis, Chinese Medical Journal, 115, 705 Contreras, 2004, Sequential therapies for proliferative lupus nephritis, The New England Journal of Medicine, 350, 971, 10.1056/NEJMoa031855 Ginzler, 2005, Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis, The New England Journal of Medicine, 353, 2219, 10.1056/NEJMoa043731 Chan, 2005, Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis, Journal of the American Society of Nephrology, 16, 1076, 10.1681/ASN.2004080686 Grootscholten, 2007, Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis, Arthritis & Rheumatism, 56, 924, 10.1002/art.22449 Chan, 2005, Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine, Lupus, 14, 265, 10.1191/0961203305lu2081oa Cush, 2005 Bertsias, 2007, EULAR recommendations for the management of Systemic Lupus Erytematosus (SLE) Report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)*, Annals of the Rheumatic Diseases Barile-Fabris, 2005, Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus, Annals of the Rheumatic Diseases, 64, 620, 10.1136/ard.2004.025528 Mok, 1998, Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome, The Journal of Rheumatology, 25, 467 Stojanovich, 2003, Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study), Lupus, 12, 3, 10.1191/0961203303lu251oa Neuwelt, 1995, Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus, American Journal of Medicine, 98, 32, 10.1016/S0002-9343(99)80078-3 Lewis, 1992, A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group, The New England Journal of Medicine, 326, 1373, 10.1056/NEJM199205213262101 Zhou, 2006, [Neuropsychiatric manifestations in systemic lupus erythematosus and the treatment of intrathecal methotrexate plus dexamethasone], Zhonghua Yi Xue Za Zhi, 86, 771 Carneiro, 1999, Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus, The Journal of Rheumatology, 26, 1275 Rahman, 1998, Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis, The Journal of Rheumatology, 25, 243 McCune, 2007 Petri, 2001, Arava in Lupus. American College of Rheumatology 65th Annual Scientific Meeting, Arthritis and Rheumatism, 44 Sato, 2001, Methotrexate therapy in systemic lupus erythematosus, Lupus, 10, 162, 10.1191/096120301666080831 Morton, 2000, An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use, Annals of the Rheumatic Diseases, 59, 487, 10.1136/ard.59.6.487 Wallace, 2007, Additional Therapies Used in the Management of Lupus. Dubois' Lupus Erythematosus Kreuter, 2004, Pimecrolimus 1% cream for cutaneous lupus erythematosus, Journal of the American Academy of Dermatology, 51, 407, 10.1016/j.jaad.2004.01.044 Lampropoulos, 2004, Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative, Rheumatology (Oxford), 43, 1383, 10.1093/rheumatology/keh325 Anonymous. http://www.fda.gov/fdac/departs/2006/206_upd.html#eczema. Journal [serial on the Internet]. Last accessed April 2006. Date. Wallace, 2006, What's new in the management of lupus since 2000?, Journal of Clinical Rheumatology, 12, 307, 10.1097/01.rhu.0000250481.90932.7b Sontheimer, 2006, Lupus - Specific Skin Disease (Cutaneous LE) Leandro, 2002, An open study of B lymphocyte depletion in systemic lupus erythematosus, Arthritis & Rheumatism, 46, 2673, 10.1002/art.10541 Looney, 2004, B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab, Arthritis & Rheumatism, 50, 2580, 10.1002/art.20430 Sfikakis, 2005, Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future, Current Opinion In Rheumatology, 17, 550, 10.1097/01.bor.0000172798.26249.fc Leandro, 2005, B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients, Rheumatology (Oxford), 44, 1542, 10.1093/rheumatology/kei080 Ng, 2006, Repeated B cell depletion in treatment of refractory systemic lupus erythematosus, Annals of the Rheumatic Diseases, 65, 942, 10.1136/ard.2005.044487 Tokunaga, 2007, Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system, Annals of the Rheumatic Diseases, 66, 470, 10.1136/ard.2006.057885 Sfikakis, 2005, Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial, Arthritis & Rheumatism, 52, 501, 10.1002/art.20858 Ng, 2007, B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response, Annals of the Rheumatic Diseases, 66, 1259, 10.1136/ard.2006.067124 Edwards, 2004, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, The New England Journal of Medicine, 350, 2572, 10.1056/NEJMoa032534 Vallerskog, 2007, Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE, Clinical Immunology, 122, 62, 10.1016/j.clim.2006.08.016 Alert F., Rituximab (marketed as Rituxan) Information. 12/18/2006 [updated 12/18/2006; cited]; Available from: http://www.fda.gov/cder/drug/infosheets/hcp/rituximab.pdf. Dorner, 2006, Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus, Arthritis Research & Therapy, 8, R74, 10.1186/ar1942 Human Genome Sciences. Available at: http://www.hgsi.com/products/LSB.html, editor. Furie, 2003, Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of lymphostat-B (human monocloncal antibody to BLyS) in SLE patients, Arthritis & Rheumatism, 48, S377 Furie, 2006, Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLys]) improves or stabilizes SLE activity in a multicenter phase 2 trial, Arthritis and Rheumatism, 54, S28 2007 Stohl, 2006, Changes in circulating B-cell counts, autoantibody levels and immunoglobulins that associate with therapeutic responsiveness in SLE to BLyS protein antagonism by belimumab, Arthritis & Rheumatism, 54, S780 Dall'Era M CE GM, et al. Trial of atacicept in patients with systemic lupus erythematosus. Abstract L19. ACR/ARHP Annual Scientific Meeting. November 2006. Genovese, 2005, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition, The New England Journal of Medicine, 353, 1114, 10.1056/NEJMoa050524 Westhovens, 2006, Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial, Rheumatology (Oxford), 45, 1238, 10.1093/rheumatology/kel066 Daikh, 2001, Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide, Journal of Immunology, 166, 2913, 10.4049/jimmunol.166.5.2913 Kalunian, 2002, Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, 46, 3251, 10.1002/art.10681 Boumpas, 2003, A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis, Arthritis & Rheumatism, 48, 719, 10.1002/art.10856 Freedman, 2003, CD40 ligand–assessing risk instead of damage?, The New England Journal of Medicine, 348, 1163, 10.1056/NEJMe030012 Alarcon-Segovia, 2003, LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study, Arthritis & Rheumatism, 48, 442, 10.1002/art.10763 Furie, 2001, Treatment of systemic lupus erythematosus with LJP 394, The Journal of Rheumatology, 28, 257 Mosca, 2007, LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus, Expert Opinion on Pharmacotherapy, 8, 873, 10.1517/14656566.8.6.873 Furie, 2006, Abetimus sodium (riquent) for the prevention of nephritic flares in patients with systemic lupus erythematosus, Rheumatic Diseases Clinics of North Americas, 32, 149, 10.1016/j.rdc.2005.11.001 Teva Pharmaceuticals. Available at: http://www.tevapharm.com/research/products_ai.asp Aringer, 2004, Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study, Arthritis & Rheumatism, 50, 3161, 10.1002/art.20576 Aringer, 2007, Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus, Arthritis & Rheumatism, 56, 274, 10.1002/art.22327 Debandt, 2003, Anti-TNF-alpha-induced systemic lupus syndrome, Clinical Rheumatology, 22, 56, 10.1007/s10067-002-0654-5 Favalli, 2002, Drug-induced lupus following treatment with infliximab in rheumatoid arthritis, Lupus, 11, 753, 10.1191/0961203302lu236cr Baechler, 2003, Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus, Proceedings of the National Academy of Sciences of the United States of America, 100, 2610, 10.1073/pnas.0337679100 Feng, 2006, Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus, Arthritis & Rheumatism, 54, 2951, 10.1002/art.22044 Braun-Moscovici, 2002, Stem cell therapy in scleroderma, Current Opinion In Rheumatology, 14, 711, 10.1097/00002281-200211000-00014 Burt, 2006, Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus, Journal of American Medical Association, 295, 527, 10.1001/jama.295.5.527 Jayne, 2004, Autologous stem cell transplantation for systemic lupus erythematosus, Lupus, 13, 168, 10.1191/0961203304lu525oa Petri, 2003, High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus, Arthritis & Rheumatism, 48, 166, 10.1002/art.10752 Petri, 2006, Cyclophosphamide Vs. Monthly (NIH) Cyclophosphaide: Final Results, Arthritis and Rheumatism, 54, S444